Our Chief Executive Officer Neil Wilkie will be in Stockholm from 4-6 November attending the 30th annual BIO-Europe conference. At Mironid, we are committed to transforming the treatment landscape for patients with ADPKD and other rare diseases, and we look forward to sharing our latest insights at this event! To speak with Neil, please do […]
The Mironid team will be in San Diego from 23-27 October attending Kidney Week, an annual scientific conference organised by the American Society of Nephrology. We look forward to presenting our research, with Catherine (Cass) Kelleher, MD, our Chief Medical Officer, Adele Rowley, our Chief Scientific Officer, and David J P Henderson, our Head of […]
Our Head of Biology will be in Dublin next week at Cilia2024, the world’s largest scientific meeting for cilia and ciliopathy research running 10-13 September. David will be presenting an abstract titled: “Allosteric modulation of long-form PDE4 enzymes as a potential treatment for ADPKD” on Tuesday 10 September at 12:20 BST as part of Session […]
On Saturday, the Mironid Mudders traded in their lab coats for mud, sweat, and a whole lot of fun at Tough Mudder Scotland to raise funds and awareness for the Polycystic Kidney Disease (PKD) Charity UK (PKD) Charity. A huge well done to the team for their teamwork and determination, and a massive thank you […]
Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a serious hereditary kidney disease, has successfully completed a project funded by an Innovate UK (IUK) Biomedical Catalyst grant. The project, titled “Extending Mironid’s PDE4 activator programme: Hyperparathyroidism as a second clinical indication,” commenced on March 1st, […]
Read more de Mironid Completes Successful Innovate UK Grant for Hyperparathyroidism Research
LoAc® compound lowers renal cAMP after single or multiple doses and demonstrates efficacy in a preclinical model of ADPKDMironid will select a development candidate from its LoAc® programme to advance as a treatment for ADPKD 28 May 2024, Glasgow, Scotland – Mironid, a biopharmaceutical company developing small molecule therapeutics for the treatment of Autosomal Dominant […]
Our CSO, Adele Rowley, and CMO, Cass Kelleher, will be in Stockholm next week at the European Renal Association (ERA) Congress on 23-26 May, presenting data on the effects of our LoAc® compounds on cyst formation in Autosomal Dominant Polycystic Kidney Disease (#ADPKD). Adele will present an abstract titled “Targeting cAMP in ADPKD by small […]
Read more de Mironid presenting at European Renal Association meeting
Mironid’s CEO will be in San Sebastian from 12-14 May at Bio€quity Europe, an opportunity to meet with potential investors to discuss the current issues and trends facing the biotech industry and how to rise above the noise to attract the right investors and partnerships. If you would like to meet Neil next week, please […]
Tomorrow, Mironid’s CSO will be presenting at the 2nd ACE Drug Discovery Summit taking place in London. Her presentation will outline our work developing a novel disease modifying treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). […]
Read more de Mironid CSO presenting at Drug Discovery Summit